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Synthesis of Maculalactone A and Derivatives for 
Environmental Fate Tracking Studies 
Samuel L. Bader,a Michael U. Lueschera and Karl Gademann*a 
Maculalactone A (1) constitutes a promising antifouling agent inhibiting the formation of 
biofilms in marine and freshwater systems. In this study, we developed a new route based on a 
late-stage formation of the butenolide core leading to the total synthesis of maculalactone A 
(three steps, overall yield of 45%) and delivering material on gram scale. In addition, 
analogues of the title compound were assayed concerning their biological activity utilizing 
Artemia franciscana and Thamnocephalus platyurus. The most active analogue was 
functionalized with a rhodamine B fluorophore and was utilized in an in vivo staining 
experiment in Artemia salina. Two different tissues were found to accumulate this 
maculalactone A derivative. 
 
Introduction 
The accumulation of biological material on all surfaces 
immersed in biological fluids (referred to as biofouling), is a 
serious challenge for marine vessels, fresh water treatment and 
industrial plants.1–5 The ban of previously employed tributyltin 
coatings by international organizations further aggravated this 
issue.6 A bio-inspired approach to address this problem 
constitutes the use of natural products as antifouling agents.7,8 
In the recent years, marine butenolide natural products attracted 
interest, as they show good antifouling activity and quorum-
sensing inhibition.9–12 In the context of our own research, we 
have developed several natural product based approaches to 
prevent biofouling, ranging from novel algicidal natural 
products,13–15 passivated metal oxide surfaces with antifouling 
properties16–18 to active surfaces, functionalized with natural 
products, for controlling or inhibiting bacterial growth.19,20 
The slowly growing cyanobacterium Kyrtuthrix maculans 
forms pure colonies on rocky shores, which, by the absence of 
other organisms in these colonies, suggests that some sort of 
chemical defence could be operating. Based on these 
observations, the group of Brown isolated the maculalactones, a 
family of interesting secondary metabolites, from this 
cyanobacterium (Fig. 1). While maculalactone A (1), B, C and 
L consist of a benzylated γ-lactone, maculalactone D, E, F (2), 
G, H, I, J and K (3) include an additional phenylpropanoid unit 
forming a six membered carbocycle.21–24 Maculalactone A 
constitutes the most abundant congener in this series found in 
K. maculans. In addition, Brown et al. conducted preliminary 
antifouling experiments by submerging structures coated with a 
maculalactone A containing paint in the sea.25 After 12 weeks, 
reduced area coverage with bivalves was observed. Although 
this reduction was partially compensated by an increased grow 
of algae, it demonstrated the potential of 1 as antifouling agent. 
However, little is known about the structural requirements or 
the mode of action of maculalactone A (1). In addition, the 
isolation of larger amounts of 1 from the slow-growing 
producer is unpractical and the three published total syntheses 
offer overall yields below 10%.26–28 In this study, we have 
developed an efficient preparation of maculalactone A (1), have 
performed a preliminary structure–activity relationship study 
and have investigated the environmental fate of this compound 
in model crustaceans via labelled analogues. 
 
Fig.	  1	  Selected	  maculalactones	  isolated	  from	  Kyrtuthrix	  maculans:	  Maculalactone	  
A21,	  F	  and	  K.22	  
Results and Discussion 
Improved Total Synthesis of Maculalactone A 
To access gram-scale amounts of maculalactone A (1) and its 
structural analogues, an improved synthesis had to be 
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developed. The new route should not only result in a higher 
overall yield, but should also allow for the modification of the 
different benzyl groups. We first targeted an optimization of the 
published routes to maculalactone A.26–28 A survey of those 
revealed a general problem in the nucleophilic introduction of 
benzyl groups to the butenolide core. In a first phase, we tried 
to work around such a nucleophilic benzylation. Messorosh et 
al. recently described the radical benzylation of 2,3-
dichloromaleic anhydride (4) in good yield.29 The resulting 
anhydride 6 is a central intermediate in the synthesis of Brown 
and Argade.26,27 However, the dichloride 4 is expensive and 
difficult to prepare in the laboratory. The corresponding 
dibromide 5 was synthesised30 and subjected to the same 
conditions, giving 6 in 28% yield (Scheme 1). Overall, this 
route led to no improvement when compared with the known 
syntheses of 1. 
 
Scheme	  1	   Investigated	  shortcuts	   in	  the	  total	  syntheses	  of	  Brown	  and	  Argade	  et	  
al.	  Reaction	  from	  4	  to	  6	  was	  previously	  published	  by	  Messorosh	  et	  al.29	  PTC	  =	  N-­‐
anthrylated	  quinine	  chloride	  synthesised	  as	  described	  by	  Hofstetter	  et	  al.31	  
Alternatively, a shortcut in the route of Argade27 was 
investigated by an electrophlic substitution at the γ-position of 
intermediate 7 (Scheme 1). An enantioselective phase-transfer 
catalyst mediated procedure was expected to give optically 
enriched maculalactone A. However, the benzyl group was 
directed to the α-position giving the achiral lactone 9. 
 
Scheme	  2	  Synthesis	  of	  maculalactone	  A	  by	  a	  late	  stage	  ring	  closing	  metathesis.	  
Since an improvement of the previously published routes did 
not appear feasible, new strategies were considered. Therefore, 
we focused on strategies with a late stage butenolide formation, 
thereby, avoiding benzylic disconnections. Among the various 
known methods to synthesise butenolides, only few approaches 
allow substituents in all three positions.32–34 
Alkene metathesis has been applied for butenolide syntheses by 
different groups.35–37 Diene 13 was therefore synthesised in a 
convergent fashion from the starting material 10, which was 
accessed as described by Pihko et al.38 The enal 10 was either 
converted to acid 11 applying a Pinnick oxidation or benzylated 
in a 1,2-addition to obtain alcohol 12. The two parts were 
combined in a Steglich esterification giving diene 13 in an 
overall yield of 42 respectively 38%. However, the subsequent 
metathesis reaction under optimized conditions and in the 
presence of Ti(OiPr)437 resulted in a low conversion of 11%. 
Despite this disappointing result, this route allowed for the first 
time the modification of a single benzyl moiety.  
Another potentially rewarding strategy would constitute the late 
stage preparation of the olefinic bond through an elimination 
approach. To this goal, we investigated a procedure originally 
reported by Avetisyan et al.39 in 1981 and later utilized in an 
industrial setting.40 Key to this strategy would be the 
intramolecular cyclization of 3,6-dioxo-4-oxa-1-hexanoate 
derivative 17, with subsequent loss of ethanol and CO2 
furnishing the desired butenolide (Scheme 3). In order to test 
this hypothesis, malonate 14 was saponified to the half-ester 15 
in a single step41 and converted to the corresponding anhydride 
with pivaloyl chloride. In the same pot, the anhydride 
intermediate was reacted with the known α-hydroxy ketone 16, 
which itself is accessible via a Benzoin-type Umpolung 
reaction,42 to the corresponding keto-diester 17. 
 
Scheme	   3	   Synthesis	   of	  maculalactone	   A	   by	   a	   late	   stage	   butenolide	   formation.	  
Synthesis	  of	  15	  from	  14	  as	  published	  by	  Goel	  et	  al.41	  
The key step, i.e. the late stage cyclization of 17 to the 
butenolide 1, was addressed next. After optimizing base, 
solvent and different additives, the cyclization was 
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accomplished with caesium carbonate in refluxing THF, giving 
maculalactone A (1) in a yield of 76%. In order to the drive the 
reaction to completion, and to prevent alcoholysis of 17 with 
the formed ethanol, the presence of 4 Å molecular sieves was 
found to be crucial. Interestingly, the intermolecular version of 
this reaction led to the formation of product 1, however, only 
little conversion could be observed. 
We postulate, as a working hypothesis for this interesting 
reaction, the intramolecular attack of the deprotonated malonate 
to the ketone, followed by an intramolecular transesterification 
(liberation of EtOH) and formation of a β-lactone. Subsequent 
CO2 release would then result in maculalactone A (1). The 
mechanism was studied by a series of experiments; however, 
direct mass spectrometric detection of intermediates was not 
possible. Interestingly, running the reaction in sealed tubes did 
not lead to product formation. Additional experiments will be 
necessary to study the mechanism of this transformation. 
Based on this short approach, maculalactone A (1) was 
synthesised in an overall yield of 45% in three linear steps from 
the inexpensive, commercially available starting material 14. In 
addition, this strategy allows for the differentiation of the 
benzyl groups via their sequential regioselective introduction. 
We took advantage of this approach to access analogues as 
described below. 
 
Scheme	  4	  Synthesis	  of	  first	  generation	  maculalactone	  A	  analogues	  25–27.	  PMB	  =	  
para-­‐methoxybenzyl.	  
 
Syntheses of Maculalactone A Derivatives and SAR studies 
For further investigations of the mode of action, environmental 
fate studies and potential applications in antifouling surface 
coatings, we were interested in modified maculalactone A 
derivatives. First, however, the appropriate position for  
modifications had to be identified in a structure–activity 
relationship study (SAR). We initially proposed the para-
positions of the respective benzyl groups to have a minimal 
influence on the biological activity and, therefore, the three 
structural isomers 25, 26 and 27, each bearing a methoxy group 
in the para-position were synthesised (Scheme 4). Malonate 18 
was synthesised based on a reported procedure43 and converted 
to its potassium salt 19 at reduced temperature to prevent 
decarboxylation. The differently substituted α-hydroxy ketones 
Bn–CO–CH(OH)–PMB (20) and PMB–CO–CH(OH)–Bn (21) 
were prepared from the corresponding aldehydes via formation 
of the TMS protected cyanohydrins, followed by the addition of 
the respective Grignard reagent, as described in the 
literature.44,45 The formation of ester 22–24 proceeded smoothly 
as did the ring closure (yields of 40 to 69% over two steps). 
We were then interested in profiling the biological activity of 
maculalactone A and analogs. In the work of Brown et al., the 
LC50 values of extracted maculalactone A were determined in 
ecotoxicity assays utilizing different stages of Tetraclita 
japonica, Balanus amphitrite, Ibla cumingii and Artemia 
salina,25 of which the latter is often used for reference toxicity 
experiments. For comparison, we evaluated the compounds in 
the related Artemia franciscana as well as the sensitive 
freshwater crustacean Thamnocephalus platyurus, which is 
well-established in our group.46,47  
 
Fig	  2	  Biological	  evaluation	  of	   first	  generation	  maculalactone	  A	  analogues.	  Grey:	  
A.	   franciscana,	   black:	   T.	   platyurus.	   Values	   are	   given	   as	   mean	   of	   three	  
independent	  experiments	  with	  ten	  animals;	  error	  bars	  denote	  the	  standard	  error	  
of	  the	  mean	  (SEM).	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The assays show comparable (same order of magnitude), but 
slightly lower toxicity of the synthetic maculalactone A (1) in 
A. franciscana, when compared to the report of Brown et al.25 
This difference is either caused by racemic 1 or by differences 
in the assay set-up, and should not be of concern. Interestingly, 
compound 25 featuring the PMB group in the α-position 
exhibits an increased toxicity in A. franciscana, whereas 
isomeric lactones 26 and 27 display lower or no toxic effects on 
the test organism. In addition to the toxicity, the assays exposed 
a strong effect on the swimming ability of the test organisms. 
While fast movement is observed in both the blank and in a 1 
µM maculalactone A solution, upon increased concentration 
(10 µM), the ability of the animals to swim in a controlled 
manner is strongly impaired (for a video, see supplementary 
information). 
	  
 
Scheme	  5	  Deprotection	  and	  modification	  of	  the	  most	  active	  maculalactone	  A	  analogue	  25.	  EtO(CH2CH2O)3Ts	  was	  prepared	  as	  described	  in	  literature.
48,49	  Compound	  
32	  was	  synthesised	  as	  described	  by	  Yan	  et	  al.50	  
As analogue 25 showed a similar or higher toxicity as the 
parent maculalactone A, it was used for further derivatisation 
studies. The methoxy group was quantitatively cleaved in the 
presence of boron tribromide to give phenol 28, which was 
coupled with different residues. First, etherification with a 
triethylene glycol unit,48,49 gave the short PEGylated lactone 29. 
After mesitylation of phenol 28, it was coupled with an 
octylborane derivative in a Suzuki reaction, affording 
compound 30. Furthermore, phenol 28 was added to the 
activated PEG azide 31. By a Click reaction, this intermediate 
was connected to the rhodamine B derivative 3250 giving the 
fluorescently labelled maculalactone A analogue 33. 
Additionally, compound 34 with a free hydroxyl group instead 
of the maculalactone A moiety was synthesised as a negative 
control. However, this compound proved to be unstable (amide 
hydrolysis), and, after repeated purification, could only be 
obtained in very low yield. 
Consequently, the PEGylated compound 29 and the 
fluorescently labelled, rhodamine B derivative 33 were 
subjected to the toxicity assay with A. franciscana (Fig. 3). 
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Surprisingly, compound 29, with the short PEG residue, did not 
display any toxicity in this assay. However, the rhodamine B 
bearing analogue 33 exhibited toxicity comparable to the one 
observed for 1. Therefore, this fluorescent analogue 33 was 
used as a model to examine the distribution of maculalactone A 
in crustaceans. 
 
Fig	   3	   Toxicological	   tests	   of	   modificated	   maculalactone	   A	   analogues	   using	   A.	  
franciscana	   as	   test	   organism.	   Values	   are	   given	   as	  mean	   of	   three	   independent	  
experiments	  with	  ten	  animals,	  error	  bars	  denote	  the	  standard	  error	  of	  the	  mean	  
(SEM).	  
Visualization of Maculalactone A Distribution in Artemia salina 
The media of A. franciscana was found to be incompatible with 
subsequent visualization steps (fixation with formalin). 
Therefore, a more robust species of A. salina was employed for 
the in vivo experiments with the rhodamine B labelled 
macualalctone A derivative 33.  
 
Fig	   4	   Overlay	   of	   four	   microscope	   pictures	   of	   A.	   salina	   nauplia	   stained	   with	  
compound	  33	  (visual	  and	  fluorescence	  images).	  Scale	  bar	  =	  100	  μm.	  
A marker concentration of 1 µM was found to be optimal, as no 
toxic effects were determined at this level. The two days old 
animals were incubated for 24 hours in 1 µM solutions of the 
marked maculalactone A 33, the negative control 34, 
rhodamine B and a blank solution. This was followed by a 
washing procedure were the crustaceans were twice transferred 
in fresh media and incubated for three hours. Finally, the larvae 
were fixed in a formalin solution in PBS puffer. The stained 
and fixed organisms were examined by fluorescence 
microscopy under identical lighting conditions (see supporting 
information for micrographs). While rhodamine B led to a 
general staining of the entire body, the negative control 34 did 
not show any fluorescence at all. In contrast, the 
macualalactone A marker 33 led to a well defined distribution 
in the animal with a selective staining of certain organs (Fig 4). 
A highly stained rod-shaped tissue in the centre of the body is 
observed, which can be attributed to the intestine,51 and is 
sharply terminated towards the tail region.  
 
Fig	  5	  Tail	  region	  of	  Artemia	  salina	  nauplia	  stained	  with	  compound	  33.	  Visual	  and	  
fluorescence	  images,	  10	  μm	  slides	  in	  the	  z-­‐axis,	  scale	  bar	  =	  50	  μm.	  
Further support for this observation stems from examination by 
a confocal microscope, which disclosed more details of this 
region. Slices through the animal (Figure 5) reveal a tube-like 
structure, which is in agreement with the hypothesis that the 
intestine, but not its content, is stained by the marker 33. 
Further evidence is presented by the well-defined localization 
of the fluorescently labelled natural product 33, which can be 
rationalized by a selective staining and little or no diffusion. A 
similar, well-defined staining is observed towards the head 
region (see supporting information for details). In summary, the 
evidence presented supports the notion that the labelled 
maculalactone A derivative is accumulated in the animal in 
well-defined tissue. However, as little is known about the 
anatomy of A. salina in larvae stage, more detailed assignment 
of the involved tissues will require further experiments based 
on the preliminary successful use of the fluorescently labelled 
probe 33. 
Conclusions 
In conclusion, we have developed a new and efficient route to 
maculalactone A (1) that delivered gram-amounts of materials 
in three steps and 45 % overall yield. The key step of the 
synthesis employed a late stage butenolide formation involving 
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an intramolecular malonate addition with subsequent extrusion 
of CO2. This route enabled the preparation of macualalcatone 
analogues 25, 26 and 27, of which their biological activity was 
compared in a toxicity assay using A. franciscana and T. 
platyurus. Significant activity was observed with compound 25, 
which was further modified. The rhodamine B labelled 
derivative 33 proved to be the most interesting for tissue 
distribution and environmental fate studies in A. salina. 
Staining of specific tissues of the organisms supported the 
hypothesis that selective targets can be reached by 
maculalactone in the animal. However, further investigations 
are required to understand the distribution of maculalactone A 
(1) on living organisms, which should be enabled by the probe 
reported herein. 
Experimental section 
All chemicals have been purchased from Acros, Alfa Aesar, 
Fluka or Sigma-Aldrich and were used without further 
purification if not otherwise reported. Solvents applied for 
chemical transformations were either puriss quality or HPLC 
grade solvents. Dry solvents were purchased from Sigma-
Aldrich. Technical grade solvents for extractions and 
chromatography were distilled before usage. Air or moisture 
sensitive reactions were set up in dry glassware under nitrogen 
atmosphere. All synthetic transformations have been monitored 
by either thin layer chromatography (TLC) or 1H-NMR 
spectroscopy. Yields refer to purified, dried and spectro- 
scopically pure compounds. TLC was performed on Merck 
silica gel 60 F254 plates. The developed plates were examined 
under UV light at 254 nm and stained with an aqueous 
KMnO4/Na2CO3 solution. Concentration was performed by 
rotary evaporation at 40 °C under reduced pressure (unless 
otherwise stated). Flash chromatography was performed using 
silica gel 60 (230–400 mesh) from Merck or Silicycle with a 
forced flow eluent at 0.1–0.3 bar pressure. All 1H- and 
13C-NMR spectra were recorded using a Bruker DPX-NMR 
400 MHz (1H) and 100 MHz (13C) or a Bruker Avance DRX 
500 MHz (1H) and 125 MHz (13C) spectrometer at room 
temperature. Chemical shifts (δ-values) are reported in ppm, 
spectra were calibrate related to solvents’ residual proton 
chemical shifts, multiplicity is reported as follows: s = singlet, d 
= doublet, t = triplet or m = multiplet and coupling constant J in 
Hz. IR spectra were recorded on a Varian 800 FT-IR ATR 
spectrophotometer. The absorptions are reported in cm−1. Mass 
spectra were recorded either on a high-resolution Bruker maXis 
4G spectrometer using elecrospray ionization (HR-MS) or a 
Finnigan MAT 95Q spectrometer using electronic inonization 
(EI-MS). Elementary analysis (EA) was measured on a Perkin-
Elmer Analysator 240. HPLC analysis was performed with a 
Dionex-Chromatography system using a P680 pump and a 
PDA-100 detector. Preparative reversed-phase HPLC was 
performed using Varian Prep Star pumps and a Dionex 
UltiMate 3000 RS detector or a Dionex P680 pump and a 
Dionex PDA-100 detector. Melting points (Mp) were determined 
using a Büchi B545 apparatus in open capillaries and are 
uncorrected. Absorptions spectra (UV/VIS) were recorded on a 
Shimadzu UV-1650 PC instrument. Emission spectra were 
recorded on a Shimadzu RF-5301 PC instrument. Additional 
procedures and characterization data can be found in the 
electronic supplementary information (ESI), see DOI: 
10.1039/b000000x 
Potassium 2-benzyl-3-ethoxy-3-oxopropanoate (15) 
A published procedure41 was modified as follows: To a solution 
of diethyl benzylmalonate (14, 5.11 g, 20.0 mmol, 1.00 eq.) in 
EtOH (20 ml) was added a freshly filtered solution of 
potassium hydroxide (1.39 g, 21.0 mmol, 1.05 eq.) in EtOH (20 
ml) at room temperature. The reaction was stirred for six hours 
at room temperature. The precipitate was filtered off and the 
filtrate was concentrated to a yellowish foam. The residue was 
suspended twice in Et2O and again concentrated. After drying 
at high vacuum, the foam was triturated overnight in Et2O (50 
ml). The precipitate was isolated by filtration to give the title 
compound 15 (4.44 g, 17 mmol, 85%) as white solid. 1H-NMR 
(400 MHz, D2O): 7.30–7.22 (m, 2H), 7.22–7.15 (m, 3H), 4.06–
3.96 (m, 2H), 3.51 (dd, J = 8.8, 7.4 Hz, 1H), 3.05–3.00 (m, 2H), 
1.07 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, D2O): 176.0, 
173.3, 139.1, 128.7, 128.6, 126.6, 62.0, 57.3, 35.0, 13.2. IR 
(neat): 3396, 2980, 1710, 1598, 1496, 1454, 1359, 1321, 1234, 
1150, 1095, 1061, 1028, 950, 914, 858, 830, 745, 698. HRMS: 
Calculated for C12H13O4 [M-K]-: 221.0819, found: 221.0822. 
Mp: 120 °C (decomposition). The analytical data match those 
reported in the literature.41  
3-Hydroxy-1,4-diphenylbutan-2-one (16) 
A published procedure42 was modified as follows: To a solution 
of sodium acetate (328 mg, 4.00 mmol, 0.200 eq.) and freshly 
distilled phenyl acetaldehyde (4.77 ml, 40.0 mmol, 2.00 eq.) in 
EtOH (20 ml) was added 
3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (540 
mg, 2.00 mmol, 0.100 eq.). The mixture was heated to reflux 
for three hours, cooled down and mixed with ice water (20 ml). 
After stirring for another hour, the mixture was saturated with 
NaCl and extracted three times with EtOAc. The org. layers 
were washed with brine, combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column 
chromatography (SiO2, pentane/EtOAc (7:1 to 5:1)) to give the 
title compound 16 (2.9 g, 12 mmol, 61%) as yellow liquid, 
which crystallized after several days. 1H-NMR (500 MHz, 
CDCl3): 7.39–7.26 (m, 6H), 7.25–7.12 (m, 4H), 4.51 (ddd, J = 
7.4, 5.5, 4.9 Hz, 1H), 3.81 (d, J = 15.9 Hz, 1H), 3.75 (d, J = 
15.9 Hz, 1H), 3.22 (d, J = 5.6 Hz, 1H), 3.15 (dd, J = 14.1, 4.7 
Hz, 1H), 2.90 (dd, J = 14.1, 7.4 Hz, 1H). 13C-NMR (126 MHz, 
CDCl3): 209.2, 136.5, 133.1, 129.6, 129.5, 128.9, 128.8, 127.5, 
127.2, 76.8, 45.9, 40.3. The analytical data match those 
reported in the literature.42,44  
1-Ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-benzylmalonate (17) 
as a mixture of diastereomers 
To a suspension of potassium 2-benzyl-3-ethoxy-3-
oxopropanoate (19.0 g, 72.8 mmol, 15, 1.40 eq.) in dry THF 
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(250 ml) at 0 °C was added DMF (201 µl, 5.20 mmol, 0.050 
eq.) followed by the dropwise addition of pivaloyl chloride 
(11.0 ml, 88.4 mmol, 1.70 eq.) over five minutes. During the 
addition of pivaloyl chloride, the reaction mixture turned to a 
solution and after another 10 minutes to a gel. This gel was then 
kept for one hour at 0 °C and for 2.5 hours at room temperature, 
during which the gel turned back into a solution. The resulting 
solution was concentrated, dried in high vacuum, again 
dissolved in dry CH2Cl2 (250 ml), concentrated and dried again 
in high vacuum without exceeding a temperature of 25 °C. The 
residue was dissolved in dry CH2Cl2 (250 ml) and cooled to 0 
°C. The addition of 4-dimethylaminopyridine (635 mg, 5.20 
mmol, 0.100 eq.) to the reaction mixture was followed by the 
addition of a solution of 3-hydroxy-1,4-diphenylbutan-2-one 
(16, 12.5 g, 52.0 mmol, 1.00 eq.) in dry CH2Cl2 (50 ml) over 10 
minutes. The reaction was allowed to reach room temperature 
overnight before it was quenched at 0 °C with a mixture of 
water and a sat. aq. NaHCO3 solution (1:1 v/v). The layers were 
separated and the aq. layer was extracted three times with 
CH2Cl2. The org. layers were washed with a sat. aq. NH4Cl 
solution, combined, dried with Na2SO4 and concentrated. The 
crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (6:1)) to give the title compound 17 (23.1 g, 52 
mmol, quantitative) as yellowish liquid. Rf (SiO2, pentane/Et2O 
(2:1)): 0.7. 1H-NMR (500 MHz, CDCl3): 7.32–7.20 (m, 8H), 
7.20–7.15 (m, 2H), 7.14–7.09 (m, 2H), 7.06–6.99 (m, 3H), 
5.35–5.25 (m, 1H), 4.21–4.04 (m, 2H), 3.76–3.69 (m, 1H), 3.58 
(s, 1H), 3.50 (d, J = 16.9 Hz, 0.5H), 3.38 (d, J = 16.9 Hz, 0.5H), 
3.26–3.11 (m, 2H), 3.06–2.93 (m, 2H), 1.19–1.11 (m, 3H). 13C-
NMR (126 MHz, CDCl3): 204.4, 204.3, 168.5, 168.4, 168.4, 
168.3, 137.7, 137.6, 135.7, 135.5, 132.9, 132.9, 129.9, 129.9, 
129.6, 129.6, 129.0, 129.0, 128.7, 128.7, 128.7, 127.3, 127.3, 
127.2, 127.1, 127.1, 79.6, 79.4, 61.9, 61.9, 53.8, 53.7, 46.5, 
46.4, 37.1, 34.7, 34.7, 14.1, 14.1. IR (neat): 3031, 2982, 2936, 
1732, 1497, 1454, 1369, 1276, 1229, 1149, 701, 633. HRMS: 
Calculated for C28H32NO5 [M+NH4]+: 462.2275, found: 
462.2274. EI-MS (70 eV) m/z (%): 444(3, [M]+), 353 (9), 205 
(43), 160 (10), 159 (100), 131 (68), 91 (94). 
Maculalactone A (1) 
A two neck round bottom flask was equipped with a condenser 
and a device to run the condensed solvent over a bed of 4 Å 
molecular sieves. In the flask, a mixture of cesium carbonate 
(1.23 g, 3.78 mmol, 0.200 eq.) and THF (400 ml) was heated 
until the suspension was strongly refluxing. After refluxing for 
30 minutes, a solution of 1-ethyl 3-(3-oxo-1,4-diphenylbutan-2-
yl) 2-benzylmalonate (17, 8.40 g, 18.9 mmol, 1.00 eq.) in THF 
(20 ml) was added over 25 minutes. The reaction was further 
stirred under strong reflux. After 3.5 hours, the finished 
reaction was cooled to room temperature. The mixture was 
filtrated over a bed of SiO2 and the solids were washed with 
TBME. The filtrate was concentrated. The crude product was 
purified by recrystallization from water and methanol to give 
the title compound 1 (5.1 g, 14 mmol, 76%) as off-white 
crystals. 1H-NMR (400 MHz, CDCl3): 7.34–7.23 (m, 6H), 
7.22–7.10 (m, 5H), 7.03 (d, J = 6.5 Hz, 2H), 6.92–6.85 (m, 2H), 
4.99–4.89 (m, 1H), 3.92 (d, J = 15.6 Hz, 1H), 3.63 (d, J = 15.3 
Hz, 1H), 3.57 (d, J = 15.3 Hz, 1H), 3.48 (d, J = 15.6 Hz, 1H), 
3.23 (dd, J = 14.5, 3.9 Hz, 1H), 2.82 (dd, J = 14.6, 6.1 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): 173.7, 161.8, 137.8, 136.1, 
135.0, 129.6, 129.2, 128.8, 128.7, 128.3, 127.5, 127.3, 126.5, 
81.7, 77.4, 38.1, 33.4, 29.5. The analytical data match those 
reported in the literature.26  
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